Department of Radiology, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Gyeonggi, Republic of Korea.
Department of Radiology, Haeundae Sharing and Happiness Hospital, 502, Jwadongsunhwan-ro, Haeundae-gu, Busan, 48101, Republic of Korea.
Eur Radiol. 2021 Sep;31(9):6446-6456. doi: 10.1007/s00330-021-07808-x. Epub 2021 Mar 13.
Confidence in long-term treatment results of thermal ablation for papillary thyroid microcarcinoma (PTMC) is required in comparison with active surveillance. The objective of this meta-analysis is to report 5-year follow-up results of thermal ablation for PTMC.
Ovid MEDLINE and EMBASE databases were searched through May 30, 2020, for studies reporting outcomes in patients with PTMC treated with thermal ablation and followed up for at least 5 years. Data were extracted and methodological quality was assessed independently by two radiologists according to the PRISMA guidelines.
Three studies, involving 207 patients with 219 PTMCs, met the inclusion criteria through database searches. None of these patients experienced local tumor recurrence, lymph node metastasis, or distant metastasis or underwent delayed surgery during a mean pooled 67.8-month follow-up. Five new tumors appeared in the remaining thyroid gland of four patients, with four of these tumors successfully treated by repeat thermal ablation. The pooled mean major complication rate was 1.2%, with no patient experiencing life-threatening or delayed complications.
Thermal ablation is an excellent local tumor control method in patients with low-risk PTMC, with low major complication rates at 5 years.
• No local tumor recurrence, lymph node metastasis, or distant metastasis was noted by thermal ablation during follow-up of 5 years and none underwent delayed surgery. • The pooled mean major complication rate was 1.2%.
与主动监测相比,需要对甲状腺微小乳头状癌(PTMC)热消融的长期治疗结果有信心。本荟萃分析的目的是报告 PTMC 热消融的 5 年随访结果。
通过 Ovid MEDLINE 和 EMBASE 数据库,检索截至 2020 年 5 月 30 日,报道接受热消融治疗并至少随访 5 年的 PTMC 患者结局的研究。两位放射科医生根据 PRISMA 指南独立提取数据并评估方法学质量。
通过数据库搜索,有 3 项研究符合纳入标准,共纳入 207 例 219 个 PTMC 患者。在平均 67.8 个月的随访中,这些患者均无局部肿瘤复发、淋巴结转移或远处转移,也无需进行延迟手术。4 例患者的剩余甲状腺中出现 5 个新肿瘤,其中 4 个肿瘤通过重复热消融成功治疗。总的主要并发症发生率为 1.2%,无患者发生危及生命或延迟性并发症。
对于低危 PTMC 患者,热消融是一种出色的局部肿瘤控制方法,5 年时主要并发症发生率较低。
• 热消融在 5 年随访中未发现局部肿瘤复发、淋巴结转移或远处转移,也无需进行延迟手术。• 总的主要并发症发生率为 1.2%。